Ivana Knezevic

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5478515/publications.pdf

Version: 2024-02-01

45 papers	1,881 citations	361413 20 h-index	289244 40 g-index
61 all docs	61 docs citations	61 times ranked	3233 citing authors

#	Article	IF	Citations
1	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	9.1	355
2	WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet, The, 2021, 397, 1347-1348.	13.7	308
3	Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. Biologicals, 2015, 43, 298-306.	1.4	114
4	WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe, The, 2022, 3, e235-e240.	7.3	108
5	Demonstrating vaccine effectiveness during a waning epidemic: A WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. Vaccine, 2019, 37, 863-868.	3.8	60
6	Adventitious agents in viral vaccines: Lessons learned from 4 case studies. Biologicals, 2014, 42, 223-236.	1.4	45
7	Scientific considerations for the regulatory evaluation of cell therapy products. Biologicals, 2017, 50, 20-26.	1.4	43
8	Evaluation of cell substrates for the production of biologicals: Revision of WHO recommendations. Biologicals, 2010, 38, 162-169.	1.4	39
9	The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals, 2020, 65, 1-9.	1.4	34
10	WHO Informal Consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22â€“23 September 2009. Vaccine, 2010, 28, 6945-6950.	3.8	30
11	An overview of the immunogenicity and effectiveness of current human rabies vaccines administered by intradermal route. Vaccine, 2019, 37, A99-A106.	3.8	30
12	Human challenge trials in vaccine development, Rockville, MD, USA, September 28â€“30, 2017. Biologicals, 2019, 61, 85-94.	1.4	29
13	Biosimilars â€“ Global issues, national solutions. Biologicals, 2011, 39, 252-255.	1.4	28
14	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. Npj Vaccines, 2021, 6, 83.	6.0	25
15	Regulatory challenges with biosimilars: an update from 20 countries. Annals of the New York Academy of Sciences, 2021, 1491, 42-59.	3.8	20
16	Regulatory evaluation of biosimilars throughout their product life-cycle. Bulletin of the World Health Organization, 2018, 96, 281-285.	3.3	20
17	Thiomersal in vaccines: a regulatory perspective. Vaccine, 2004, 22, 1836-1841.	3.8	19
18	Case studies on clinical evaluation of biosimilar monoclonal antibody: Scientific considerations for regulatory approval. Biologicals, 2015, 43, 1-10.	1.4	18

#	Article	IF	Citations
19	Immunogenicity assessment of monoclonal antibody products: A simulated case study correlating antibody induction with clinical outcomes. Biologicals, 2015, 43, 307-317.	1.4	17
20	Review of efficacy trials of HIV-1/AIDS vaccines and regulatory lessons learned. Biologicals, 2016, 44, 73-89.	1.4	17
21	Stability evaluation of vaccines: WHO approach. Biologicals, 2009, 37, 357-359.	1.4	16
22	WHO standards for biotherapeutics, including biosimilars: an example of the evaluation of complex biological products. Annals of the New York Academy of Sciences, 2017, 1407, 5-16.	3.8	16
23	Prevalence of oncogenic Human papillomavirus and genetic diversity in the L1 gene of HPV16 HPV 18 HPV31 and HPV33 found in women from Vojvodina Province Serbia. Biologicals, 2019, 58, 57-63.	1.4	16
24	Vaccine qualityâ€”can a single standard be defined?. Vaccine, 2002, 20, 1000-1003.	3.8	14
25	Report of an international collaborative study to establish the suitability of using modified ATP assay for viable count of BCG vaccine. Vaccine, 2008, 26, 4754-4757.	3.8	14
26	Report of the international conference on next generation sequencing for adventitious virus detection in biologicals. Biologicals, 2018, 55, 1-16.	1.4	14
27	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs, 2022, 36, 359-371.	4.6	14
28	International regulatory requirements for vaccine safety and potency testing: a WHO perspective&. Procedia in Vaccinology, 2011, 5, 164-170.	0.4	13
29	Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody. Npj Vaccines, 2019, 4, 42.	6.0	13
30	Report on a WHO consultation on the characterisation of BCG vaccines, WHO, Geneva, Switzerland 8â€“9 Dec 2004. Vaccine, 2005, 23, 5700-5704.	3.8	12
31	WHO/KFDA joint workshop on implementing WHO guidelines on evaluating similar biotherapeutic products, Seoul, Republic of Korea 24â€“26 August, 2010. Biologicals, 2011, 39, 349-357.	1.4	11
32	Working Group on quality, safety and efficacy of typhoid Vi capsular polysaccharide conjugate, vaccines, Jeju, Republic of Korea, 5â€“7 September 2012. Vaccine, 2013, 31, 4466-4469.	3.8	11
33	High-risk human papilloma virus genotypes in cervical carcinoma of Serbian women: Distribution and association with pathohistological findings. Biologicals, 2016, 44, 412-416.	1.4	9
34	Evaluation of similar biotherapeutic products (SBPs): Scientific principles and their implementation. Biologicals, 2011, 39, 256-261.	1.4	8
35	Removal of the innocuity test from The International Pharmacopoeia and WHO recommendations for vaccines and biological products. Biologicals, 2020, 66, 17-20.	1.4	8
36	Quality assessment and its impact on clinical performance of a biosimilar erythropoietin: A simulated case study. Biologicals, 2019, 62, 8-15.	1.4	6

#	Article	IF	Citations
37	Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines â€“ A review from a regulatory perspective. Biologicals, 2016, 44, 90-110.	1.4	5
38	WHO informal consultation on the guidelines for evaluation of the quality, safety, and efficacy of DNA vaccines, Geneva, Switzerland, December 2019. Npj Vaccines, 2020, 5, 52.	6.0	3
39	Biosimilars â€“ status in July 2020 in 16 countries. GaBI Journal, 2021, 10, 4-32.	0.3	3
40	Biosimilars. , 2018, , 345-358.		2
41	WHO informal consultation on revision of guidelines on evaluation of similar biotherapeutic products, virtual meeting, 30 June â€“ 2 July 2021. Biologicals, 2022, 76, 1-9.	1.4	2
42	1st WHO International Standard antiserum to RSV: Availability and benefits for RSV vaccine development (Commentary on the collaborative study report published in the vaccine journal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 537	3.8	1
43	Animal cell substrates for the production of biologicals: An introduction to WHO documents. Biologicals, 2014, , 101090.	1.4	0
44	Review of the current use and evaluation of cell substrates for producing biologicals in selected countries. Biologicals, 2015, 43, 153-157.	1.4	0
45	WHO consultation on clinical evaluation of vaccines, 17â€“18 July 2014, WHO Headquarters, Geneva, Switzerland. Vaccine, 2015, 33, 1999-2003.	3.8	0